全文获取类型
收费全文 | 6405篇 |
免费 | 439篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 235篇 |
妇产科学 | 147篇 |
基础医学 | 862篇 |
口腔科学 | 121篇 |
临床医学 | 599篇 |
内科学 | 1392篇 |
皮肤病学 | 113篇 |
神经病学 | 642篇 |
特种医学 | 133篇 |
外国民族医学 | 1篇 |
外科学 | 621篇 |
综合类 | 67篇 |
一般理论 | 4篇 |
预防医学 | 690篇 |
眼科学 | 81篇 |
药学 | 446篇 |
中国医学 | 19篇 |
肿瘤学 | 666篇 |
出版年
2024年 | 28篇 |
2023年 | 87篇 |
2022年 | 169篇 |
2021年 | 287篇 |
2020年 | 200篇 |
2019年 | 218篇 |
2018年 | 253篇 |
2017年 | 195篇 |
2016年 | 215篇 |
2015年 | 201篇 |
2014年 | 299篇 |
2013年 | 341篇 |
2012年 | 612篇 |
2011年 | 623篇 |
2010年 | 335篇 |
2009年 | 264篇 |
2008年 | 384篇 |
2007年 | 414篇 |
2006年 | 374篇 |
2005年 | 362篇 |
2004年 | 288篇 |
2003年 | 244篇 |
2002年 | 204篇 |
2001年 | 27篇 |
2000年 | 10篇 |
1999年 | 17篇 |
1998年 | 48篇 |
1997年 | 28篇 |
1996年 | 21篇 |
1995年 | 19篇 |
1994年 | 24篇 |
1993年 | 9篇 |
1992年 | 6篇 |
1991年 | 7篇 |
1990年 | 7篇 |
1989年 | 6篇 |
1988年 | 5篇 |
1987年 | 8篇 |
1986年 | 3篇 |
1985年 | 4篇 |
1984年 | 5篇 |
1983年 | 3篇 |
1982年 | 8篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1978年 | 4篇 |
1977年 | 1篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1969年 | 1篇 |
排序方式: 共有6875条查询结果,搜索用时 15 毫秒
41.
42.
43.
Paola Indovina Francesca Pentimalli Nadia Casini Immacolata Vocca Antonio Giordano 《Oncotarget》2015,6(20):17873-17890
Inactivation of the retinoblastoma (RB1) tumor suppressor is one of the most frequent and early recognized molecular hallmarks of cancer. RB1, although mainly studied for its role in the regulation of cell cycle, emerged as a key regulator of many biological processes. Among these, RB1 has been implicated in the regulation of apoptosis, the alteration of which underlies both cancer development and resistance to therapy. RB1 role in apoptosis, however, is still controversial because, depending on the context, the apoptotic cues, and its own status, RB1 can act either by inhibiting or promoting apoptosis. Moreover, the mechanisms whereby RB1 controls both proliferation and apoptosis in a coordinated manner are only now beginning to be unraveled. Here, by reviewing the main studies assessing the effect of RB1 status and modulation on these processes, we provide an overview of the possible underlying molecular mechanisms whereby RB1, and its family members, dictate cell fate in various contexts. We also describe the current antitumoral strategies aimed at the use of RB1 as predictive, prognostic and therapeutic target in cancer. A thorough understanding of RB1 function in controlling cell fate determination is crucial for a successful translation of RB1 status assessment in the clinical setting. 相似文献
44.
Michelandrea De Cesare Denis Cominetti Valentina Doldi Alessia Lopergolo Marcello Deraco Paolo Gandellini Sharon Friedlander Yosef Landesman Michael G. Kauffman Sharon Shacham Marzia Pennati Nadia Zaffaroni 《Oncotarget》2015,6(15):13119-13132
Survivin, which is highly expressed and promotes cell survival in diffuse malignant peritoneal mesothelioma (DMPM), exclusively relies on exportin 1 (XPO1/CRM1) to be shuttled into the cytoplasm and perform its anti-apoptotic function. Here, we explored the efficacy of Selective Inhibitors of Nuclear Export (SINE), KPT-251, KPT-276 and the orally available, clinical stage KPT-330 (selinexor), in DMPM preclinical models. Exposure to SINE induced dose-dependent inhibition of cell growth, cell cycle arrest at G1-phase and caspase-dependent apoptosis, which were consequent to a decrease of XPO1/CRM1 protein levels and the concomitant nuclear accumulation of its cargo proteins p53 and CDKN1a. Cell exposure to SINE led to a time-dependent reduction of cytoplasmic survivin levels. In addition, after an initial accumulation, the nuclear protein abundance progressively decreased, as a consequence of an enhanced ubiquitination and proteasome-dependent degradation. SINE and the survivin inhibitor YM155 synergistically cooperated in reducing DMPM cell proliferation. Most importantly, orally administered SINE caused a significant anti-tumor effect in subcutaneous and orthotopic DMPM xenografts without appreciable toxicity. Overall, we have demonstrated a marked efficacy of SINE in DMPM preclinical models that may relay on the interference with survivin intracellular distribution and function. Our study suggests SINE-mediated XPO1/CRM1 inhibition as a novel therapeutic option for DMPM. 相似文献
45.
Federica Verginelli Laura Adesso Isabelle Limon Anna Alisi Marie Gueguen Nadia Panera Ezio Giorda Lavinia Raimondi Roberta Ciarapica Antonio F. Campese Isabella Screpanti Stefano Stifani Jan Kitajewski Lucio Miele Rossella Rota Franco Locatelli 《Oncotarget》2015,6(41):43216-43229
The Notch1 and Notch4 signaling pathways regulate endothelial cell homeostasis. Inflammatory cytokines induce the expression of endothelial adhesion molecules, including VCAM1, partly by downregulating Notch4 signaling. We investigated the role of endothelial Notch1 in this IL-1β-mediated process. Brief treatment with IL-1β upregulated endothelial VCAM1 and Notch ligand Jagged1. IL-1β decreased Notch1 mRNA levels, but levels of the active Notch1ICD protein remained constant. IL-1β-mediated VCAM1 induction was downregulated in endothelial cells subjected to pretreatment with a pharmacological inhibitor of the γ-secretase, which activates Notch receptors, producing NotchICD. It was also downregulated in cells in which Notch1 and/or Jagged1 were silenced.Conversely, the forced expression of Notch1ICD in naïve endothelial cells upregulated VCAM1 per se and amplified IL-1β-mediated VCAM1 induction. Jagged1 levels increased and Notch4 signaling was downregulated in parallel. Finally, Notch1ICD and Jagged1 expression was upregulated in the endothelium of the liver in a model of chronic liver inflammation.In conclusion, we describe here a cell-autonomous, pro-inflammatory endothelial Notch1-Jagged1 circuit (i) triggering the expression of VCAM1 even in the absence of inflammatory cytokines and (ii) enhancing the effects of IL-1β. Thus, IL-1β regulates Notch1 and Notch4 activity in opposite directions, consistent with a selective targeting of Notch1 in inflamed endothelium. 相似文献
46.
47.
Moore CL Lu M Cheema F Osaki-Kiyan P Perri MB Donabedian S Haque NZ Zervos MJ 《Antimicrobial agents and chemotherapy》2011,55(10):4581-4588
Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of bloodstream infection (BSI) and is often associated with invasive infections and high rates of mortality. Vancomycin has remained the mainstay of therapy for serious Gram-positive infections, particularly MRSA BSI; however, therapeutic failures with vancomycin have been increasingly reported. We conducted a comprehensive evaluation of the factors (patient, strain, infection, and treatment) involved in the etiology and management of MRSA BSI to create a risk stratification tool for clinicians. This study included consecutive patients with MRSA BSI treated with vancomycin over 2 years in an inner-city hospital in Detroit, MI. Classification and regression tree analysis (CART) was used to develop a risk prediction model that characterized vancomycin-treated patients at high risk of clinical failure. Of all factors, the Acute Physiology and Chronic Health Evaluation II (APACHE-II) score, with a cutoff point of 14, was found to be the strongest predictor of failure and was used to split the population into two groups. Forty-seven percent of the population had an APACHE-II score < 14, a value that was associated with low rates of clinical failure (11%) and mortality (4%). Fifty-four percent of the population had an APACHE-II score ≥ 14, which was associated with high rates of clinical failure (35%) and mortality (23%). The risk stratification model identified the interplay of three other predictors of failure, including the vancomycin MIC as determined by Vitek 2 analysis, the risk level of the source of BSI, and the USA300 strain type. This model can be a useful tool for clinicians to predict the likelihood of success or failure in vancomycin-treated patients with MRSA bloodstream infection. 相似文献
48.
Bahriye Aktas Tanja N. Fehm Manfred Welslau Volkmar Müller Diana Lüftner Florian Schütz Peter A. Fasching Wolfgang Janni Christoph Thomssen Isabell Witzel Erik Belleville Michael Untch Marc Thill Hans Tesch Nina Ditsch Michael P. Lux Maggie Banys-Paluchowski Cornelia Kolberg-Liedtke Andreas D. Hartkopf Achim Wckel Hans-Christian Kolberg Elmar Stickeler Nadia Harbeck Andreas Schneeweiss 《Geburtshilfe und Frauenheilkunde》2022,82(9):922
For the treatment of patients with advanced HER2-negative hormone receptor-positive breast cancer, several substances have been introduced into practice in recent years. In addition, other drugs are under development. A number of studies have been published over the past year which have shown either an advantage for progression-free survival or for overall survival. This review summarizes the latest results, which have been published at current congresses or in specialist journals, and classifies them in the clinical treatment context. In particular, the importance of therapy with CDK4/6 inhibitors – trastuzumab deruxtecan, sacituzumab govitecan and capivasertib – is discussed. For trastuzumab deruxtecan, an overall survival benefit in HER2-negative breast cancer with low HER2 expression (HER2-low expression) was reported in the Destiny-Breast-04 study. Similarly, there was an overall survival benefit in the FAKTION study with capivasertib. The lack of overall survival benefit for palbociclib in the first line of therapy raises the question of clinical classification.Key words: advanced breast cancer, chemotherapy, endocrine therapy, antibody drug conjugates 相似文献
49.
Paulina M Kowalewska Jacob Fletcher William F Jackson Suzanne E Brett Michelle SM Kim Galina Yu Mironova Nadia Haghbin David M Richter Nathan R Tykocki Mark T Nelson Donald G Welsh 《Journal of cerebral blood flow and metabolism》2022,42(9):1693
Cerebral blood flow is a finely tuned process dependent on coordinated changes in arterial tone. These changes are strongly tied to smooth muscle membrane potential and inwardly rectifying K+ (KIR) channels are thought to be a key determinant. To elucidate the role of KIR2.1 in cerebral arterial tone development, this study examined the electrical and functional properties of cells, vessels and living tissue from tamoxifen-induced smooth muscle cell (SMC)-specific KIR2.1 knockout mice. Patch-clamp electrophysiology revealed a robust Ba2+-sensitive inwardly rectifying K+ current in cerebral arterial myocytes irrespective of KIR2.1 knockout. Immunolabeling clarified that KIR2.1 expression was low in SMCs while KIR2.2 labeling was remarkably abundant at the membrane. In alignment with these observations, pressure myography revealed that the myogenic response and K+-induced dilation were intact in cerebral arteries post knockout. At the whole organ level, this translated to a maintenance of brain perfusion in SMC KIR2.1−/− mice, as assessed with arterial spin-labeling MRI. We confirmed these findings in superior epigastric arteries and implicated KIR2.2 as more functionally relevant in SMCs. Together, these results suggest that subunits other than KIR2.1 play a significant role in setting native current in SMCs and driving arterial tone. 相似文献
50.
Tanja N. Fehm Manfred Welslau Volkmar Müller Diana Lüftner Florian Schütz Peter A. Fasching Wolfgang Janni Christoph Thomssen Isabell Witzel Milena Beierlein Erik Belleville Michael Untch Marc Thill Hans Tesch Nina Ditsch Michael P. Lux Bahriye Aktas Maggie Banys-Paluchowski Cornelia Kolberg-Liedtke Andreas D. Hartkopf Achim Wckel Hans-Christian Kolberg Nadia Harbeck Elmar Stickeler 《Geburtshilfe und Frauenheilkunde》2023,83(3):289
The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from the APHINITY study, and on how preoperative peritumoral application of local anesthetics can influence the prognosis. We also present solid data on dynamic Ki-67 from the ADAPT studies.Key words: breast cancer, surgery, chemotherapy, therapy standard 相似文献